Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma

Objective To analyze the efficacy and safety of PD-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma. Methods We collected the data of patients with advanced neuroendocrine carcinoma who had failed the first-line standard chemotherapy and treated with PD-1 inhibitor combined w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	YU Xuxu, LI Xiangke, YANG Minjie, CHEN Zhong, MAO Yinggang, SONG Lijie
Formato:	article
Lenguaje:	ZH
Publicado:	Magazine House of Cancer Research on Prevention and Treatment 2021
Materias:	immune checkpoint inhibitor pd-1 anlotinib neuroendocrine carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/186b970ee9bb445ab2de5a5302123faf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:186b970ee9bb445ab2de5a5302123faf
record_format	dspace
spelling	oai:doaj.org-article:186b970ee9bb445ab2de5a5302123faf2021-11-05T02:22:52ZEfficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma1000-857810.3971/j.issn.1000-8578.2021.21.0271https://doaj.org/article/186b970ee9bb445ab2de5a5302123faf2021-10-01T00:00:00Zhttp://html.rhhz.net/ZLFZYJ/html/8578.2021.21.0271.htmhttps://doaj.org/toc/1000-8578Objective To analyze the efficacy and safety of PD-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma. Methods We collected the data of patients with advanced neuroendocrine carcinoma who had failed the first-line standard chemotherapy and treated with PD-1 inhibitor combined with anlotinib from the First Affiliated Hospital of Zhengzhou University. Results A total of 45 patients, including 24 males and 21 females, were included. The median age was 57 years old. The primary tumor sites were lung (23 cases, 51.1%), esophagus (8 cases, 17.8%), pancreas (7 cases, 15.6%) and rectum (7 cases, 15.6%). Eighteen cases (40%) had failed the first- and second-line treatments, and 27 cases (60%) had failed the third-line and above treatments. All patients received 2-15 cycles of treatment, 3 cases died due to disease progression, overall objective response rate was 11.1%, disease control rate was 53.5%, median progression-free survival was 5.8 months, and 10-month progression-free survival rate was 25.5%. Adverse events were mainly grade 1-2 myelosuppression and digestive tract reactions. Conclusion PD-1 combined with anlotinib show better efficacy and good tolerance on advanced neuroendocrine carcinoma. It can be used as a choice after the failure of standard first-line treatment of advanced neuroendocrine carcinoma.YU XuxuLI XiangkeYANG MinjieCHEN ZhongMAO YinggangSONG LijieMagazine House of Cancer Research on Prevention and Treatmentarticleimmune checkpoint inhibitorpd-1anlotinibneuroendocrine carcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHZhongliu Fangzhi Yanjiu, Vol 48, Iss 10, Pp 974-978 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	immune checkpoint inhibitor pd-1 anlotinib neuroendocrine carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immune checkpoint inhibitor pd-1 anlotinib neuroendocrine carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 YU Xuxu LI Xiangke YANG Minjie CHEN Zhong MAO Yinggang SONG Lijie Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
description	Objective To analyze the efficacy and safety of PD-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma. Methods We collected the data of patients with advanced neuroendocrine carcinoma who had failed the first-line standard chemotherapy and treated with PD-1 inhibitor combined with anlotinib from the First Affiliated Hospital of Zhengzhou University. Results A total of 45 patients, including 24 males and 21 females, were included. The median age was 57 years old. The primary tumor sites were lung (23 cases, 51.1%), esophagus (8 cases, 17.8%), pancreas (7 cases, 15.6%) and rectum (7 cases, 15.6%). Eighteen cases (40%) had failed the first- and second-line treatments, and 27 cases (60%) had failed the third-line and above treatments. All patients received 2-15 cycles of treatment, 3 cases died due to disease progression, overall objective response rate was 11.1%, disease control rate was 53.5%, median progression-free survival was 5.8 months, and 10-month progression-free survival rate was 25.5%. Adverse events were mainly grade 1-2 myelosuppression and digestive tract reactions. Conclusion PD-1 combined with anlotinib show better efficacy and good tolerance on advanced neuroendocrine carcinoma. It can be used as a choice after the failure of standard first-line treatment of advanced neuroendocrine carcinoma.
format	article
author	YU Xuxu LI Xiangke YANG Minjie CHEN Zhong MAO Yinggang SONG Lijie
author_facet	YU Xuxu LI Xiangke YANG Minjie CHEN Zhong MAO Yinggang SONG Lijie
author_sort	YU Xuxu
title	Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
title_short	Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
title_full	Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
title_fullStr	Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
title_full_unstemmed	Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
title_sort	efficacy and safety of pd-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma
publisher	Magazine House of Cancer Research on Prevention and Treatment
publishDate	2021
url	https://doaj.org/article/186b970ee9bb445ab2de5a5302123faf
work_keys_str_mv	AT yuxuxu efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT lixiangke efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT yangminjie efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT chenzhong efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT maoyinggang efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma AT songlijie efficacyandsafetyofpd1inhibitorcombinedwithanlotinibonadvancedneuroendocrinecarcinoma
_version_	1718444515069526016

Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma

Ejemplares similares